louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00851955: Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Official title: Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pancreatitis
Pancreatic Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2009-02-26
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary Care

Brief summary: The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.


Eligibility criteria: Inclusion Criteria:

* Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
* Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
* Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Exclusion Criteria:

* Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Primary outcomes:
measure: All cause mortality
timeFrame: One year
Secondary outcomes:
measure: For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice.
timeFrame: One year
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Massimo Raimondo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01243255: Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Official title: Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia. Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: hypercholesterolemia
low density lipoprotein
undertreatment of hypercholesterolemia
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-11-18
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: The purpose of the survey is to evaluate the efficacy of treatment of hypercholesterolemia in Polish patients who are currently on lipid- lowering pharmacological therapy . Efficient treatment is defined as achievement of the LDL cholesterol level goals according to the European Society of Cardiology 2007 guidlines.


Eligibility criteria: Inclusion Criteria:

* Patients on lipid lowering drug treatment
* Lipid lowering drug treatment lasting at least 3 months
* No lipid lowering drug/dose change for a minimum 6 weeks prior to enrolment to the study

Exclusion Criteria:

* Lack of patient's signed informed consent form
* Lack of the blood sample taken for lipid profile and glucose within 10 days before or after assessment of the patient

Primary outcomes:
measure: establish the proportion of patients on lipid lowering pharmacological treatment reaching the LDL-C goals according to ESC 2007 guidelines in general.
timeFrame: whole study procedure takes place during the one, single patient's visit
Secondary outcomes:
measure: establish the proportion of patients on lipid lowering pharmacological treatment in primary prevention, reaching the LDL-C goals according to ESC 2007 guidelines for this sub-population
timeFrame: whole study procedure takes place during the one, single patient's visit
measure: establish the proportion of patients on lipid lowering pharmacological treatment in secondary prevention, reaching the LDL-C goals according to ESC 2007 guidelines for this sub-population
timeFrame: whole study procedure takes place during the one, single patient's visit
measure: identify determinants (patient and physician characteristics) for undertreatment of hypercholesterolemia.
timeFrame: whole study procedure takes place during the one, single patient's visit
Other outcomes:
Locations:
Study officials:
affiliation: Medical University of Warsaw
name: Prof. Artur Mamcarz
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca Pharma
name: Barbara Możejko-Pastewka
role: STUDY_DIRECTOR
References:
Clinical trial NCT04023955: Promoting HPV Vaccine Through Twitter
Official title: Feasibility of a Twitter Campaign to Promote HPV Vaccine Uptake Among Racially/Ethnically Diverse Young Adult Women Living in Public Housing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Human Papilloma Virus
Keywords: vaccination
feasibility
public housing
Lead sponsor: Tufts University
Sponsor class: OTHER
First posted: 2019-07-18
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women residing in public housing Ages18-26 years No history of cervical cancer

Brief summary: This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing.

Detailed description: Investigators recruited a convenience sample (n=35) of women ages 18-26 years who resided in public housing in Massachusetts. Investigators assessed the feasibility and acceptability of the campaign. Online assessed changes in HPV knowledge, attitudes, and vaccine intentions before and after the campaign.

Eligibility criteria: Inclusion Criteria:

English-speaking women Age18-26 years Residents of public housing in two Massachusetts cities

Primary outcomes:
measure: Measure of Humanpapilloma VirusVaccine Knowledge
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07023055: Multicenter Prospective Cohort Study on TAM Receptor Tyrosine Kinase Ligands for Predicting the Severity of Acute Pancreatitis
Official title: Multicenter Prospective Cohort Study on TAM Receptor Tyrosine Kinase Ligands for Predicting the Severity of Acute Pancreatitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Pancreatic Necrosis
Acute Pancreatitis (AP)
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
Collaborators: name: The first affiliated Hospital of Nanjing Medical University, Jiangsu Province
First posted: 2025-06-15
Enrollment: 896
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosed with AP based on at least two of the following criteria (1) acute onset of upper abdominal pain; (2) more than three times the upper limit of the normal range of serum lipase or amylase levels; and (3) typical radiological findings of AP on computed tomography (CT), magnetic resonance imaging, or ultrasonography.

Brief summary: AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.


Eligibility criteria: Inclusion Criteria:

1. Age 18-80 years.
2. Patients diagnosed with acute pancreatitis in outpatient/emergency departments, inpatient wards, or health examination centers starting from 2024.

Exclusion Criteria:

1. Patients with chronic pancreatitis or pancreatic cancer.
2. Pregnant or lactating women.
3. Patients who did not provide informed consent.
4. Patients with severe organic diseases, such as malignant tumors, acute myocardial infarction, or large-scale cerebral infarction.

Primary outcomes:
measure: AP severity
timeFrame: 2 days
Secondary outcomes:
measure: Organ dysfunction and failure
timeFrame: 2 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01261455: Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
Official title: Prospective Randomized Pilot Study Comparing the Surgical Times Between Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pterygium
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2010-12-16
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if there is any difference in the surgical time when the surgery is performed with a graft taken from under the upper lid versus lower lid. The investigators will also be recording the level of pain felt by patients after surgery, any difficulties during or after surgery, and if the pterygium grows back.


Eligibility criteria: Inclusion Criteria:

* Primary pterygium (no previous surgeries or radiotherapy) requiring excision due to ocular discomfort or disruption in vision
* Ability to understand the nature of the procedure and to complete all measurement requirements
* Patients must be eligible for either the superior or inferior conjunctival autografts (they must not meet any of the following exclusion criteria)
* Adults (age \>18)

Exclusion Criteria:

* Ocular surface disease apart from pterygium (such as severe dry eye, corneal disease, scarring from previous infection, radiotherapy, inflammatory diseases or trauma)
* Patients who have had previous ocular surface surgery
* Patients with glaucoma or those who may need glaucoma surgery in the future
* Contraindications to local anesthetics (such as known allergy)
* Pregnancy (as the risk to the fetus with the use of topical antibiotic drops and local anesthetics are not known)

Primary outcomes:
measure: Time taken to complete the surgical procedure (minutes)
timeFrame: 1 year
Secondary outcomes:
measure: Visual Analog Pain Score
timeFrame: 1 week
measure: Recurrence of pterygium
timeFrame: 1 year
measure: Intraoperative and Postoperative Complications
timeFrame: 6 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto Western Hospital, University of Toronto
state: Ontario
Study officials:
affiliation: Toronto Western Hospital, University of Toronto
name: Allan Slomovic, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04359355: Computer-aided Detection of Colorectal Polyps
Official title: Development and Validation of a New Artificial Intelligence System for Automated Detection of Colorectal Polyps During Colonoscopy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adenoma Colon
Polyp of Colon
Keywords: colonoscopy
endoscopy
adenoma detection
polyp detection
artificial intelligence
Lead sponsor: University of Erlangen-Nürnberg Medical School
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients presenting between January and May 2020 for surveillance or Screening colonoscopy in the Ludwig Demling Endoscopy Center of Excellence will be prospectively included under the above mentioned inclusion and exclusion criteria. Prior to enrollment, written informed consent will be obtained.

Brief summary: In this observational pilot study, we assess the diagnostic performance of an artificial intelligence sytem for automated detection of colorectal polyps.

Detailed description: During standard colonoscopy, a substantial number of colorectal polyps can be missend. As shown in a recent meta-analysis, miss rates for adenomas can reach up to 26%. In this study, it is tested whether an artificial intelligence system that highlights colorectal polyps during screening or surveillance colonoscopy in real time can lead to an increased detection of colorectal polyps during the examination.

Eligibility criteria: Inclusion Criteria:

* Screening or surveillance colonoscopy

Exclusion Criteria:

* known or suspected inflammatory bowel disease
* uncontrolled coagulopathy
* known polyps or referral for polypectomy

Primary outcomes:
measure: Feasibility to use the AI System in vivo during colonoscopy
timeFrame: 4 month
Secondary outcomes:
measure: Diagnostic Performance of the AI System for detecting colorectal polyps
timeFrame: 4 month
Other outcomes:
Locations:
city: Erlangen
country: Germany
facility: University Hospital Erlangen
Study officials:
References:
citation: Pfeifer L, Neufert C, Leppkes M, Waldner MJ, Hafner M, Beyer A, Hoffman A, Siersema PD, Neurath MF, Rath T. Computer-aided detection of colorectal polyps using a newly generated deep convolutional neural network: from development to first clinical experience. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e662-e669. doi: 10.1097/MEG.0000000000002209.
Clinical trial NCT03516955: Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
Official title: Observational Study of Superstat® (Rosuvastatin) in Hypercholesterolemia Patients in Lebanon
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Hypercholesterolemia
Keywords: Superstat
Rosuvastatin
Statins
LDL-C
Cholesterol
Hypercholesterolemia
Dyslipidemia
Coronary Artery Disease
Cardiovascular Disease
Lead sponsor: Hikma Pharmaceuticals LLC
Sponsor class: INDUSTRY
First posted: 2018-05-07
Enrollment: 317
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients were recruited from 24 cardiology, endocrinology and general practitioner outpatient clinics in Lebanon

Brief summary: This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary prevention based on their total cardiovascular risk. No visits or interventions, additional to the routine clinical practice, were requested or performed.

Detailed description: An observational, multicenter, prospective study of Lebanese adult (18 years or older) hypercholesterolemic patients administered generic Rosuvastatin (Superstat®).

Eligible newly diagnosed hypercholesterolemic patients took generic Rosuvastatin as prescribed by their treating physician. Assigning patients to generic Rosuvastatin was decided within the current practice and medical indication and was independent from the recruitment into the study.

Patients were followed-up at the clinic as per the standard practice of care. Each patient was followed-up for a period of 2 months.

Eligibility criteria: Inclusion Criteria:

* Males and females ≥ 18 years of age
* Patients with dyslipidemia requiring statin therapy according to CV risk factors as per the ESC/EAS 2011 guidelines for primary or secondary prevention
* Patients provided written informed consent

Exclusion Criteria:

* Age \<18 years
* Statin use in the past 3 months
* Any contraindication to HMG-CoA reductase inhibitors
* Co-administration of non-statin lipid lowering agent (ezitimibe, fibrates, niacin, omega 3)
* Conditions which may cause secondary dyslipidemia
* Any of the following abnormal laboratory tests:

TG level of \> 400 mg/dL, Abnormal liver enzymes (AST or ALT) ≥ 3 ULN, Abnormal serum creatine kinase (CK) \> 5 ULN

Primary outcomes:
measure: Percent change in mean low-density lipoproteins (LDL-C)
timeFrame: 2 months
Secondary outcomes:
measure: Percent change in mean total cholesterol, triglycerides, high density lipoprotein (HDL-C)
timeFrame: 2 months
measure: Proportion of patients who meet their target (LDL-C)
timeFrame: 2 months
measure: Incidence rate of adverse events (AEs) in association with generic rosuvastatin
timeFrame: 2 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00988455: Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Basal Cell Carcinoma
Keywords: basal cell carcinoma
photodynamic therapy
photo chemotherapy
basal cell epithelioma
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-10-02
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of photodynamic therapy (PDT)in treatment of Basal cell carcinoma (BCC) and recurrence rate after 6 months.

Detailed description: Background and Aim:

Basal cell carcinoma (BCC) is the most common skin cancer .Photodynamic therapy _as a novel , non-invasive therapeutic approach _may be considered a valuable strategy. This study was designed with the aim of the evaluation of efficacy of PDT in treatment of BCC and recurrence rate after 6 months .

Materials and Methods:

This was a clinical trial which was done on 28 BCCs. Patients were treated with ALA-PDT monthly for 1-6 sessions and evaluated for clinical response,cosmetic results,recurrence rate and probable side effects.

Eligibility criteria: Inclusion Criteria:

* Histologically proven BCCs

Exclusion Criteria:

* Rodent ulcer
* Morphea type
* ANA +
* History of photosensitivity or photodermatosis or ingestion of phototoxic drugs during last month
* Pregnancy
* Breast feeding
* Age\< 18
* History of another therapeutic intervention for bcc during last 6 months

Primary outcomes:
measure: response rate at the end of therapy protocol (regarding tumor diameter and/or pathologic examination)
timeFrame: 1 year
Secondary outcomes:
measure: recurrence rate(regarding clinical and/or pathological examination) after 6 months of follow up
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: skin research center
name: zohreh Tehranchi-nia, assist.prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00504855: Cast Sores With Waterproof Vs. Standard Cast Padding
Official title: Cast Sores With Waterproof Vs. Standard Cast Padding in a Pediatric Population
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pressure Ulcer
Keywords: Pressure ulcer
Waterproof
Gortex
Cast padding
Pediatric
Heel
Lead sponsor: Shriners Hospitals for Children
Sponsor class: OTHER
First posted: 2007-07-20
Enrollment: 84
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare waterproof cast padding material to standard cotton/poly-cotton cast padding material to the presence or absence of cast sores of the heel.

Detailed description: Cast sores result in pain, scarring and sometimes disfigurement. No study has specifically evaluated the efficacy of waterproof cast padding with respect to preventing lower extremity cast sores.

Comparison: Non-blinded randomization to waterproof or cotton/cotton-poly cast padding material in a pediatric population who have lower extremity casts that include the foot and are applied in the operating room. Comparison of cast sore incidence will be made in the two randomized groups.

Eligibility criteria: Inclusion Criteria:

* Patient at Shriners Hospital for Children - Honolulu
* Ages 0-18
* Short leg, long leg, spica or Petrie cast that includes the foot
* Cast applied in the operating room

Exclusion Criteria:

* Ponsetti casts (club foot casts with no more surgery than Achilles tenotomy, age \< 1 year)
* Splints
* cylinder casts or spicas which don't include the foot

Primary outcomes:
measure: Presence or absence of cast sores, including size, location, grade using Wagner's Classification system for the severe diabetic foot ulcerations
timeFrame: Time of cast application to final cast removal
Secondary outcomes:
measure: Presence of: abrasion; pressure/sheer; maceration wetness; infection; cast modification.
timeFrame: Cast application to final cast removal
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Shriners Hospitals for Children - Honolulu
state: Hawaii
Study officials:
affiliation: Shriners Hospitals for Children, Honolulu
name: Jonathan B Pellett, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shriners Hospitals for Children, Honolulu
name: Arabella I Leet, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wagner FW Jr. Treatment of the diabetic foot. Compr Ther. 1984 Apr;10(4):29-38. No abstract available.